This approval marks the first time patients with chronic hepatitis C virus (HCV) genotype 3 have a 12-week, once-daily, all-oral treatment option. Daklinza is indicated for use with sofosbuvir for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback